Trevena, Inc.
TRVN
Rank in Stocks
#34487
Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and... Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.
Share Price
$0.0111
Last synced: 2026-11-09
Market Cap
$9.47K
Change (1 day)
0.00%
Change (1 year)
-7.50%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Trevena, Inc. (TRVN)
Category
Healthcare
EPS for Trevena, Inc. (TRVN)
EPS as of September 2024 TTM: $-21.60
According to Trevena, Inc.'s latest financial reports, its current EPS (TTM) is $-21.60. At the end of 2023 the company had an EPS of $-3.16, an increase over its 2022 EPS of $-7.59.
EPS history for Trevena, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-21.60 | 583.54% |
| 2023 | $-3.16 | -58.37% |
| 2022 | $-7.59 | -3.92% |
| 2021 | $-7.90 | 37.39% |
| 2020 | $-5.75 | -24.84% |
| 2019 | $-7.65 | -26.86% |
| 2018 | $-10.46 | -65.40% |
| 2017 | $-30.23 | -38.48% |
| 2016 | $-49.14 | 70.39% |
| 2015 | $-28.84 | -42.78% |
| 2014 | $-50.40 | 123.11% |
| 2013 | $-22.59 | -20.49% |
| 2012 | $-28.41 | -25.30% |
| 2011 | $-38.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -172.50% |
US
|
|
| $-7.07 | -67.27% |
US
|
|
| $-5.29 | -75.51% |
AU
|
|
| $12.88 | -159.63% |
BE
|
|
| $21.56 | -199.81% |
NL
|
Questions about Trevena, Inc.'s earnings per share (EPS)
What is Trevena, Inc.'s earnings per share (EPS)?
Trevena, Inc.'s earnings per share (EPS) over the last twelve months is $-21.60, as of Sep 2024.
What was Trevena, Inc.'s earnings per share (EPS) in 2023?
In 2023, Trevena, Inc.'s earnings per share (EPS) was $-3.16, compared with $-7.59 in 2022.
How has Trevena, Inc.'s earnings per share (EPS) changed since 2018?
From 2018 to 2023, Trevena, Inc.'s earnings per share (EPS) was highest in 2023 ($-3.16) and lowest in 2018 ($-10.46).
How does Trevena, Inc.'s earnings per share (EPS) compare with similar companies?
Trevena, Inc.'s earnings per share (EPS) ($-21.60) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.